

Granted IN450418

Hydrazide based hdac3 selective inhibitors



NEED

Existing embodiments may limit the scope of inventive applications, suggesting a need for further innovation in histone deacetylase 3 inhibitors.

SOLUTION

The invention provides potent, selective HDAC3 inhibitors with a novel benzoylhydrazide scaffold and a simplified synthesis process, enhancing drug development efficiency

INNOVATION

This invention introduces a compound selectively inhibiting HDAC enzymes, with a unique structure for enhanced HDAC3 specificity and a streamlined synthesis, offering significant advancements in therapeutic applications and manufacturing efficiency.

MARKET ANALYSIS

Market: Pharmaceutical industry, particularly in cancer therapeutics

CAGR: Around 7-10% (based on the latest trends in the pharmaceutical industry)

Potential Indian Clients: Pharmaceutical companies involved in cancer research and drug development, research institutions focusing on cancer therapeutics

WHY INVEST?

Epigenetic

Selective Inhibitors

Genetic expression

Benzoylhydrazide



AT A GLANCE

- Current TRL NA
- Funded by NA
- IPC C07D
- Domain
Chemistry, Pharmaceutical Sciences



Ghosh Balam, Biswas Swati, Ganesh Routholla, Sravani Pulya, Patel Tarun

Department of, Pharmacy
BITS Pilani, Hyderabad Campus

For more information, reach out to (contact person), (designation), (organization) at (email ID) and (phone number)

